96 related articles for article (PubMed ID: 10216319)
1. Expression, purification and crystallization of recombinant human TRAIL.
Cha SS; Shin HC; Choi KY; Oh BH
Acta Crystallogr D Biol Crystallogr; 1999 May; 55(Pt 5):1101-4. PubMed ID: 10216319
[TBL] [Abstract][Full Text] [Related]
2. High-level production of soluble tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in high-density cultivation of recombinant Escherichia coli using a combined feeding strategy.
Shen YL; Zhang Y; Sun AY; Xia XX; Wei DZ; Yang SL
Biotechnol Lett; 2004 Jun; 26(12):981-4. PubMed ID: 15269523
[TBL] [Abstract][Full Text] [Related]
3. Influence of expressed TRAIL on biophysical properties of the human leukemic cell line Jurkat.
Chen K; Li D; Jiang YH; Yao WJ; Wang XJ; Wei XC; Gao J; Xie LD; Yan ZY; Wen ZY; Chien S
Cell Res; 2004 Apr; 14(2):161-8. PubMed ID: 15115618
[TBL] [Abstract][Full Text] [Related]
4. Refolding and purification of Apo2l/TRAIL produced as inclusion bodies in high-cell-density cultures of recombinant Escherichia coli.
Shen YL; Xia XX; Zhang Y; Liu JW; Wei DZ; Yang SL
Biotechnol Lett; 2003 Dec; 25(24):2097-101. PubMed ID: 14969416
[TBL] [Abstract][Full Text] [Related]
5. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL.
Bodmer JL; Meier P; Tschopp J; Schneider P
J Biol Chem; 2000 Jul; 275(27):20632-7. PubMed ID: 10748154
[TBL] [Abstract][Full Text] [Related]
6. The secretable form of trimeric TRAIL, a potent inducer of apoptosis.
Kim MH; Billiar TR; Seol DW
Biochem Biophys Res Commun; 2004 Sep; 321(4):930-5. PubMed ID: 15358116
[TBL] [Abstract][Full Text] [Related]
7. Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma.
Toomey NL; Deyev VV; Wood C; Boise LH; Scott D; Liu LH; Cabral L; Podack ER; Barber GN; Harrington WJ
Oncogene; 2001 Oct; 20(48):7029-40. PubMed ID: 11704827
[TBL] [Abstract][Full Text] [Related]
8. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells.
Kayagaki N; Yamaguchi N; Nakayama M; Takeda K; Akiba H; Tsutsui H; Okamura H; Nakanishi K; Okumura K; Yagita H
J Immunol; 1999 Aug; 163(4):1906-13. PubMed ID: 10438925
[TBL] [Abstract][Full Text] [Related]
9. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5.
Hymowitz SG; Christinger HW; Fuh G; Ultsch M; O'Connell M; Kelley RF; Ashkenazi A; de Vos AM
Mol Cell; 1999 Oct; 4(4):563-71. PubMed ID: 10549288
[TBL] [Abstract][Full Text] [Related]
10. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation.
Mongkolsapaya J; Grimes JM; Chen N; Xu XN; Stuart DI; Jones EY; Screaton GR
Nat Struct Biol; 1999 Nov; 6(11):1048-53. PubMed ID: 10542098
[TBL] [Abstract][Full Text] [Related]
11. Anti-human hepatocellular carcinoma effects of tumor necrosis factor-related apoptosis-inducing ligand in vitro & in vivo.
Guo BC; Xu YH
Acta Pharmacol Sin; 2001 Sep; 22(9):831-6. PubMed ID: 11749866
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
[TBL] [Abstract][Full Text] [Related]
13. Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity.
Johnsen AC; Haux J; Steinkjer B; Nonstad U; Egeberg K; Sundan A; Ashkenazi A; Espevik T
Cytokine; 1999 Sep; 11(9):664-72. PubMed ID: 10479402
[TBL] [Abstract][Full Text] [Related]
14. Specificity of molecular recognition learned from the crystal structures of TRAIL and the TRAIL:sDR5 complex.
Cha SS; Song YL; Oh BH
Vitam Horm; 2004; 67():1-17. PubMed ID: 15110168
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of a new member of the TNF family that induces apoptosis.
Wiley SR; Schooley K; Smolak PJ; Din WS; Huang CP; Nicholl JK; Sutherland GR; Smith TD; Rauch C; Smith CA
Immunity; 1995 Dec; 3(6):673-82. PubMed ID: 8777713
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan.
Déjosez M; Ramp U; Mahotka C; Krieg A; Walczak H; Gabbert HE; Gerharz CD
Cell Death Differ; 2000 Nov; 7(11):1127-36. PubMed ID: 11139287
[TBL] [Abstract][Full Text] [Related]
17. Purification and characterization of recombinant sTRAIL expressed in Escherichia coli.
Xia XX; Shen YL; Wei DZ
Acta Biochim Biophys Sin (Shanghai); 2004 Feb; 36(2):118-22. PubMed ID: 14970907
[TBL] [Abstract][Full Text] [Related]
18. TRAIL (Apo-2L) and TRAIL receptors in human placentas: implications for immune privilege.
Phillips TA; Ni J; Pan G; Ruben SM; Wei YF; Pace JL; Hunt JS
J Immunol; 1999 May; 162(10):6053-9. PubMed ID: 10229846
[TBL] [Abstract][Full Text] [Related]
19. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative.
Wajant H; Moosmayer D; Wüest T; Bartke T; Gerlach E; Schönherr U; Peters N; Scheurich P; Pfizenmaier K
Oncogene; 2001 Jul; 20(30):4101-6. PubMed ID: 11494138
[TBL] [Abstract][Full Text] [Related]
20. Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation.
Kemp TJ; Elzey BD; Griffith TS
J Immunol; 2003 Jul; 171(1):212-8. PubMed ID: 12817000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
